3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Thromboembolism
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
3
Capecitabine
3
Tegafur
2
Stents
2
Radiofrequency Ablation
2
Leucovorin
2
Irinotecan
2
toripalimab
1
tislelizumab
1
taxane
1
surufatinib
1
lenvatinib
1
apixaban
1
apatinib
1
aldesleukin
1
Urination
1
Trastuzumab
1
Tomography, X-Ray Computed
1
Temozolomide
1
Taxes
1
Standard of Care
1
Sorafenib
1
S 1 (combination)
1
Rivaroxaban
1
Radiotherapy
1
Polymerase Chain Reaction
1
Platinum Compounds
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gallbladder Neoplasms
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled